2039. New York State 2016–2018: Progression from Candida auris Colonization to Bloodstream Infection
Open accessAbstract
New York State (NYS) is experiencing a continuing outbreak of Candida auris, first identified in 2016. Patients who are colonized asymptomatically with C. auris can progress to bloodstream infection (BSI). Colonized patients with positive nares or axilla/groin C. auris cultures were followed prospectively. Laboratories, hospitals and skilled nursing facilities reported C. auris clinical infections to the NYS Department of Health. Patient demographics, clinical history, hospital admission, procedures, and outcomes data were obtained using a standardized case report form. Patient-days were determined from date of first positive colonization to date of first positive clinical isolate, death, or March 30, 2018, whichever was first. Between September 28, 2016 and March 30, 2018, 187 C. auris colonized patients were identified. Of these, seven progressed to BSI during at least 24,781 patient days of follow-up (median: 98 patient-days, range 0–548 days.) The median time from date of first colonization to date of BSI was 86 days (range 3–310 days). The median patient age at time of colonization was 71 years (range 57–89 years). Between colonization and BSI, patients had a median of five admissions in healthcare facilities (range 1–12). All patients had central neurologic disease, gastrostomy tubes, chronic wounds, and vascular lines at time of BSI. All patients had a positive culture for one or more other multi-drug resistant organism within 90 days of a positive C. auris culture, and all received antibiotics in the 30 days before BSI. Six (86%) patients received mechanical ventilation and had tracheostomies. Five (71%) patients had diabetes. Four (57%) had vascular lines replaced in the 30 days before BSI onset. Two (29%) cases had gastrostomy tube replacement between colonization and BSI. One patient died a week after C. auris BSI; a second died 4 months later. In NYS, 4% of C. auris colonized patients developed BSI, a rate of 0.3 BSI per 1,000 patient-days. BSI patients have portals of entry such as indwelling medical devices and wounds. Neurologic disease and diabetes may be risk factors for BSI. Meticulous aseptic technique for invasive procedures, device and wound care may help prevent C. auris BSI in colonized patients. All authors: No reported disclosures.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The 6.9% progression in this study is comparable to the 3.7% bloodstream infection rate in a New York state study.
“This finding is comparable with a smaller New York state study in which a C. auris bloodstream infection occurred in 7/187 (3.7%) colonized patients (median time from screening case testing to infection 86 days) (7).”
From Progression from <i>Candida auris</i> Colonization Screening to Clinical Case Status, United States, 2016–2023 (2025) · cites this paper as [7]
In a New York state study, a C. auris bloodstream infection occurred in 7/187 (3.7%) colonized patients, with median time from screening case testing to infection 86 days.
“This finding is comparable with a smaller New York state study in which a C. auris bloodstream infection occurred in 7/187 (3.7%) colonized patients (median time from screening case testing to infection 86 days) (7).”
From Progression from <i>Candida auris</i> Colonization Screening to Clinical Case Status, United States, 2016–2023 (2025) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Lyman, M., Forsberg, K., Reuben, J., Dang, T., Free, R., Seagle, E. E., Sexton, D. J., Soda, E., Jones, H., Hawkins, D., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7029a2 · Cited by 104 · see citing works
Baker, A. D., Gold, J. A. W., Forsberg, K., Jones, S., & Lyman, M. M. (2025) · Emerging Infectious Diseases · doi:10.3201/eid3108.250315 · Cited by 27 · see citing works
<i>Candida auris</i>: An Emerging Antimicrobial Resistance Threat
Vallabhaneni, S., Jackson, B. R., & Chiller, T. M. (2019) · Annals of Internal Medicine · doi:10.7326/m19-2205 · Cited by 25 · see citing works
Self-citationMerrill, E. D., Prudent, V., Basso, P., Rapp, E., Moghadam, P., Rodriguez, A., Hung, E., Hurabielle, C., Cheng, J., Cho, R. J., et al. (2026) · Science · doi:10.1126/science.adu6688 · Cited by 5 · see citing works
The emerging fungal pathogen <i>Candida auris</i> induces IFNγ to colonize mammalian hair follicles
Merrill, E. D., Prudent, V., Moghadam, P., Rodriguez, A., Hurabielle, C., Wells, E. K. C., Basso, P., Scharschmidt, T. C., Rosenblum, M. D., Molofsky, A. B., et al. (2025) · doi:10.1101/2025.01.15.632653 · Cited by 4 · see citing works
- Authors
- Southwick, K., Adams, E. H., Greenko, J., Ostrowsky, B., Fernandez, R., Patel, R., Quinn, M., Vallabhaneni, S., Denis, R. J., Erazo, R., Chaturvedi, S., Haley, V. B., Leach, L., Zhu, Y. C., Giardina, R., Lutterloh, E. C., & Blog, D. S.
- Affiliations
- New York State Department of Health (US)
- Centers for Disease Control and Prevention (US)
- ORCID
- Venue
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-11
- Volume
- 5
- Issue
- suppl_1
- Pages
- S594-S595
- ISSN
- 2328-8957 (ISSN-L)
- PMC
- PMC6252412
- OpenAlex
- W2903296371
- Cited by
- 26
- References
- 0
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 4 · 2023: 6 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 2
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Open Forum Infectious Diseases (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- Funders
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Yeasts and Rust Fungi Studies
- Keywords
- Candida auris, asymptomatic colonization, bloodstream infection, indwelling medical devices, central nervous system disorders, diabetes mellitus, multidrug-resistant organisms, antifungal susceptibility, antifungal susceptibility testing, nosocomial fungal infections, risk factors, mechanical ventilation, gastrostomy tube, skilled nursing facilities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review